



Myeloma Cure Summit: DEFINITIONS, METRICS, AND MILESTONES

FEBRUARY 20-21, 2026 | MIAMI, FL

February 20, 2026

8:00-8:15

INTRODUCTION

Nikhil Munshi, Vincent Rajkumar, Philippe Moreau

8:15-10:00

SESSION 1: DATA FROM LONG TERM FOLLOW UP STUDIES PART I

Chairs: Kenneth Anderson and Jesus San Miguel

8:15-8:30

IFM

Philippe Moreau

8:30-8:45

Spanish

Laura Rosinol

9:45-9:00

Italian

Mario Boccadoro

9:00-9:15

HOVON

Pieter Sonneveld

9:15-9:30

UK

Gordon Cook

9:30-9:45

Greek

Meletios Dimopoulos

9:45-10:00

German

Marc Raab

10:00-10:15

BREAK

10:15-12:00

SESSION 1: DATA FROM LONG TERM FOLLOW UP STUDIES PART II

Chairs: Kenneth Anderson and Jesus San Miguel

10:15-10:30

Arkansas

Samer Al Hadidi

10:30-10:45

Mayo

Vincent Rajkumar

10:45-11:00

ECOG SWOG

Shaji Kumar

11:00-11:15

Industry Studies With Long Follow-up

Paul Richardson

11:15-12:00

Discussion

Nizar Bahlis, Faith Davies,
Joy Ho, Evangelos Terpos

12:00-1:00

LUNCH

1:00-3:00

SESSION 2: WHAT SHOULD BE CALLED A CURE - DEFINITION

Chairs: Nikhil Munshi and Philippe Moreau

1:00-1:10

MRD Depth

Nikhil Munshi

1:10-1:20

Cure Fraction Models: What Does the Estimated Cure
Fraction Really Mean?

John Crowley

1:20-1:30

Imaging

Elena Zamagni

1:30-1:40

Sustained With or Without Treatment

Noopur Raje

1:40-1:50

Immune Reconstitution

Madhav Dhodapkar

1:50-2:00

Off-Therapy Duration

Sundar Jagannath

2:00-2:10

QOL - Return to Work Concept

Sonja Zweegman

2:10-2:20

Attaining MGUS State

Maria-Victoria Mateos

2:20-3:00

Discussion

3:00-3:30

BREAK

3:30-5:00

SESSION 3: PATIENT SUB-GROUP CONSIDERATIONS - WHO MAY BE CURABLE

Chairs: Vincent Rajkumar and Suzanne Lentzsch

3:30-3:40

Age Groups: Are Young More Likely to be Cured?

Charlotte Pawlyn

3:40-3:50

Disease Risk Considerations: HR vs SR Which One is More Curable?

Katja Weisel

3:50-4:00

Administration of the Types of Therapy: Do We Need Cytotoxic Agents for Cure?

Saad Usmani

4:00-4:10

Genomic Correlates of Cure?

Mehmet Samur

4:10-5:00

Discussion

Niccolo Bolli, Robert Orłowski, Surbhi Sidana, Raphael Szalat

5:00-6:00

SESSION 4: PATIENT VOICES

Chair: Vania Hungria and Ravi Vij

5:00-5:15

What Does it Mean for Them?

TBD

5:15-5:30

A Patient Who May be Considered Cured

TBD

5:30-6:00

Discussion

Adam Cohen, Francesca Gay, Ola Landgren, Paola Neri

February 21, 2026

8:30-10:45

SESSION 5: REVIEW OF CURATIVE MALIGNANCIES - HOW DID THEY ACHIEVE CURE? WHAT IS THEIR DEFINITION

Chairs: TBD

8:30-8:40

Testicular Cancer

TBD

8:40-8:50

Acute Myeloid Leukemia

TBD

8:50-9:00

Pediatric Leukemia

TBD

9:00-9:10

Hodgkin's Disease

TBD

9:10-9:20

High-grade Lymphoma

TBD

9:20-9:30

Chronic Myeloid Leukemia

TBD

9:30-9:40

Therapy De-escalation in Curative Cancer

TBD

9:40-9:50

Off Therapy: Time to Define Cure

TBD

9:50-10:00

What Does Late Relapse Mean in Defining Cure?

TBD

10:00-10:45

Discussion

Gareth Morgan, Adam Sperling

10:45-11:15

BREAK

11:15-1:15	SESSION 6: WHAT THERAPIES MAY LEAD TO A CURE: STUDIES AND THERAPIES ARE POTENTIALLY ABLE TO INCREASE CURE FRACTIONS	
	<i>Chairs: Shaji Kumar and Maria-Victoria Mateos</i>	
11:15-11:30	Cure Concept 1	Sagar Lonial
11:30-11:45	Cure Concept 2	Hermann Einsele
11:45-12:00	Cure Concept 3	Ajai Chari
12:00-12:15	Cure Concept 4	Niels van de Donk
12:15-12:30	Cure Concept 5 - Early Intervention	Irene Ghobrial
12:30-1:15	Discussion	Xavier Leleu, Ajay Nooka, Fredrik Schjesvold

1:15-2:30 **LUNCH**

2:30-3:30 **SESSION 7: CONSENSUS CONSIDERATION AND FUTURE STUDIES TO FURTHER REFINE CURE**

Kenneth Anderson, Shaji Kumar, Nikhil Munshi, Philippe Moreau, Vincent Rajkumar, Jesus San Miguel

The International Myeloma Society gratefully acknowledges the following organizations for their support of the summit:



Johnson & Johnson

